A new nanoemulsion formulation improves antileishmanial activity and reduces toxicity of amphotericin B

References

• Chappuis F, Sundar S, Hailu A, et al. Visceral leishmaniasis: what are the needs for diagnosis, treatment and control? Nat Rev Microbiol. 2007;5:873–882.
   PubMed Web of Science ®Google Scholar
• Monge-Maillo B, López-Vélez R. Therapeutic options for visceral leishmaniasis. Drugs. 2013;73:1863–1888.
   PubMed Web of Science ®Google Scholar
• McGwire BS, Satoskar AR. Leishmaniasis: clinical syndromes and treatment. QJM Int J Med. 2014;107:7–14.
   PubMed Web of Science ®Google Scholar
• Carneiro G, Aguiar MG, Fernandes AP, et al. Drug delivery systems for the topical treatment of cutaneous leishmaniasis. Expert Opin Drug Deliv. 2012;9:1083–1097.
   PubMed Web of Science ®Google Scholar
• Chattopadhyay A, Jafurulla M. A novel mechanism for an old drug: amphotericin B in the treatment of visceral leishmaniasis. Biochem Biophys Res Commun. 2011;416:7–12.
   PubMed Web of Science ®Google Scholar
• Thakur CP, Narayan S. A comparative evaluation of amphotericin B and sodium antimony gluconate, as first-line drugs in the treatment of Indian visceral leishmaniasis. Ann Trop Med Parasitol. 2004;98:129–138.
   PubMed Web of Science ®Google Scholar
• Torrado JJ, Espada R, Ballesteros MP, et al. Amphotericin B formulations and drug targeting. J Pharm Sci. 2008;97:405–2425.
   Web of Science ®Google Scholar
• Barratt G, Bretagne S. Optimizing efficacy of amphotericin B through nanomodification. Int J Nanomed. 2007;2:301–313.
   PubMed Web of Science ®Google Scholar
• Muller RH, Schimidt S, Buttle I, et al. SolEmuls-novel technology for the formulation of i.v. emulsions with poorly soluble drugs . Int J Pharm. 2004;269:293–302.
   PubMed Web of Science ®Google Scholar
• Lance MR, Washington C, Davis SS. Structure and toxicity of amphotericin B/triglyceride emulsion formulations. J Antimicrob Chemother. 1995;36:119–128.
   PubMed Web of Science ®Google Scholar
• Lance MR, Washington C, Davis SS. Evidence for the formation of amphotericin B-phospholipid complexes in Langmuir monolayers. Pharm Res. 1996;13:1008–1014.
   PubMed Web of Science ®Google Scholar
• Caldeira LR, Fernandes FR, Costa DF, et al. Nanoemulsions loaded with amphotericin B: a new approach for the treatment of leishmaniasis. Eur J Pharm Sci. 2015;5:125–131.
   Google Scholar
• Hörmann K, Zimmer A. Drug delivery and drug targeting with parenteral lipid nanoemulsions – a review. J Control Release. 2016;223:85–98.
   PubMed Web of Science ®Google Scholar
• Ichikawa H, Tetsuya W, Hiroyuki T, et al. Formulation considerations of gadolinium lipid nanoemulsion for intravenous delivery to tumors in neutron-capture therapy. Curr Drug Deliv. 2007;4:131–140.
   PubMedGoogle Scholar
• Santos CM, Oliveira RB, Arantes VT, et al. Amphotericin B-loaded nanocarriers for topical treatment of cutaneous leishmaniasis: development, characterization, and in vitro skin permeation studies. J Biomed Nanotechnol. 2012;8:322–329.
   PubMed Web of Science ®Google Scholar
• Assis DN, Mosqueira VCF, Vilela JMC, et al. Release profiles and morphological characterization by atomic force microscopy and photon correlation spectroscopy of 99mTechnetium-fluconazole nanocapsules. Int J Pharm. 2008;349:152–160.
   PubMedGoogle Scholar
• Paula CS, Tedesco AC, Primo FL, et al. Chloroaluminium phthalocyanine polymeric nanoparticles as photosensitisers: photophysical and physicochemical characterisation, release and phototoxicity in vitro. Eur J Pharm Sci. 2013;49:371–381.
   PubMed Web of Science ®Google Scholar
• Jain JP, Kumar N. Development of amphotericin B loaded polymersomes based on (PEG)(3)-PLA co-polymers: factors affecting size and in vitro evaluation. Eur J Pharm Sci. 2010;40:456–465.
   PubMed Web of Science ®Google Scholar
• Jain S, Pankaj UV, Swarnakar NK, et al. Gelatin coated hybrid lipid nanoparticles for oral delivery of amphotericin B. Mol Pharm. 2012;9:2542–2553.
   PubMed Web of Science ®Google Scholar
• Kato KC, Morais-Teixeira E, Reis PG, et al. Hepatotoxicity of pentavalent antimonial drug: possible role of residual Sb(III) and protective effect of ascorbic acid. Antimicrob Agents Chemother. 2014;58:481–488.
   PubMed Web of Science ®Google Scholar
• Floury J, Desrumaux A, Lardières J. Effect of high-pressure homogenization on droplet size distributions and rheological properties of model oil-in-water emulsions. Innov Food Sci Emerg Technol. 2000;1:127–134.
   Google Scholar
• Jahnke DIS, Müller RH, Benita S, et al., editors. Emulsions and nanosuspensions for the formulation of poorly soluble drugs. Stuttgart: Medpharm Scientific Publ; 2000. Chapter 12;p. 383–407.
   Google Scholar
• Noack A, Hause G, Mader K. Physicochemical characterization of curcuminoid-loaded solid lipid nanoparticles. Int J Pharm. 2012;423:440–451.
   PubMed Web of Science ®Google Scholar
• Zhang LW, Al-Suwayeh SA, Hung CF, et al. Oil components modulate the skin delivery of 5-aminolevulinic acid and its ester prodrug from oil-in-water and water-in-oil nanoemulsions. Int J Nanomed. 2011;6:693–704.
   PubMed Web of Science ®Google Scholar
• Nasr M, Nawaz S, Elhissi A. Amphotericin B lipid nanoemulsion aerosols for targeting peripheral respiratory airways via nebulization. Int J Pharm. 2012;436:611–616.
   PubMed Web of Science ®Google Scholar
• Montasser I, Fessi H, Coleman AW. Atomic force microscopy imaging of novel type of polymeric colloidal nanostructures. Eur J Pharm Biopharm. 2002;54:281–284.
   PubMed Web of Science ®Google Scholar
• Pereira MA, Mosqueira VC, Vilela JM, et al. PLA-PEG nanocapsules radiolabelled with 99mTechnetium-HMPAO: release properties and physicochemical characterization by atomic force microscopy and photon correlation spectroscopy. Eur J Pharm Sci. 2008;33:42–51.
   PubMed Web of Science ®Google Scholar
• Le TT, Pieter S, Hoa HD, et al. Determination of heat-induced effects on the particle size distribution of casein micelles by dynamic light scattering and nanoparticle tracking analysis. Int Dairy J. 2008;18:1090–1096.
   Web of Science ®Google Scholar
• Nahar M, Mishra D, Dubey V, et al. Development, characterization, and toxicity evaluation of amphotericin B-loaded gelatin nanoparticles. Nanomedicine. 2008;4:252–261.
   PubMed Web of Science ®Google Scholar
• Italia JL, Yahya MM, Singh D, et al. Biodegradable nanoparticles improve oral bioavailability of amphotericin B and show reduced nephrotoxicity compared to intravenous Fungizone®. Pharm Res. 2009;26:1324–1331.
   PubMed Web of Science ®Google Scholar
• Egito EST, Araújo IB, Damasceno BPGL, et al. Amphotericin B/emulsion admixture interactions: an approach concerning the reduction of amphotericin B Toxicity. J Pharm Sci. 2002;91:2354–2366.
   PubMed Web of Science ®Google Scholar
• Yardley V, Croft SL. A comparison of the activities of three amphotericin B lipid formulations against experimental visceral and cutaneous leishmaniasis. Int J Antimicrob Agents. 2000;13:243–248.
   PubMed Web of Science ®Google Scholar
• Gangneux JP, Sulahian A, Garin YJF, et al. Therapy of visceral leishmaniasis due to Leishmania infantum: experimental assessment of efficacy of AmBisome. Antimicrob Agents Chemother. 1996;40:1214–1218.
   PubMed Web of Science ®Google Scholar
• Mullen AB, Carter KC, Baillie AJ. Comparison of the efficacies of various formulations of amphotericin B against murine visceral leishmaniasis. Antimicrob Agents Chemother. 1997;41:2089–2092.
   PubMed Web of Science ®Google Scholar
• Paul M, Durand R, Fessi H, et al. Activity of a new liposomal formulation of amphotericin B against two strains of Leishmania infantum in a murine model. Antimicrob Agents Chemother. 1997;41:731–1734.
   Web of Science ®Google Scholar
• Dey T, Afrin F, Anam K, et al. Infectivity and virulence of Leishmania donovani promastigotes: a role for media, source, and strain of parasite. L. Eukaryot Microbiol. 2002;4:270–274.
   Google Scholar
• Escobar P, Matu S, Marques C, et al. Sensitivities of Leishmania species to hexadecylphosphocholine (miltefosine), ET-18-OCH3 (edelfosine) and amphotericin B. Acta Trop. 2002;81:151–157.
   PubMed Web of Science ®Google Scholar
• Gondal JA, Swartz RP, Rahman A. Therapeutic evaluation of free and liposome-encapsulated amphotericin B in the treatment of systemic candidiasis in mice. Antimicrob Agents Chemother. 1989;33:1544–1548.
   PubMed Web of Science ®Google Scholar
• Olsen SJ, Swerdel MR, Blue B, et al. Tissue distribution of amphotericin B lipid complex in laboratory animals. J Pharm Pharmacol. 1991;43:831–835.
   PubMed Web of Science ®Google Scholar
• Mohamed-Ahmed AH, Brocchini S, Croft SL. Recent advances in development of amphotericin B formulations for the treatment of visceral leishmaniasis. Curr Opin Infect Dis. 2012;25:695–702.
   PubMed Web of Science ®Google Scholar
• Santos DCM, Lima ML, Toledo JS, et al. Metabolomics as a tool to evaluate the toxicity of formulations containing amphotericin B, an antileishmanial drug. Toxicol Res. 2016;5:1720–1735.
   Web of Science ®Google Scholar
• Berman J. Amphotericin B formulations and other drugs for visceral leishmaniasis. Am J Trop Med Hyg. 2015;92:471–473.
   PubMed Web of Science ®Google Scholar